Global Microbiome Partnering Terms and Agreements 2010 to 2020

$3,495.00

The Global Microbiome Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2020
Number of pages
150+
Product type
Research report
Available formats
PDF document
Report edition
2
SKU
CP2121

The Global Microbiome Partnering Terms and Agreements 2010-2020 report provides an understanding and access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in microbiome partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • microbiomepartnering contract documents
  • Top microbiome deals by value

 

The Global Microbiome Partnering Terms and Agreements 2010-2020 report provides an understanding and access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter microbiomepartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors microbiometechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

 

This report provides details of the latest microbiome, oligonucletides including aptamers agreements announced in the healthcare sectors.  

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all microbiome partnering deals announced since 2010 including financial terms where available including over 170 links to online deal records of actual microbiome partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

 

The initial chapters of this report provide an orientation of microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in microbiome dealmaking with a brief summary followed by a comprehensive listing of microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by microbiome partnering company A-Z, deal type definitions and microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in microbiome partnering and dealmaking since 2010.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of microbiome technologies and products.

 

Report scope

 

Global Microbiome Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to microbiome trends and structure of deals entered into by leading companies worldwide.

 

Global Microbiome Partnering Terms and Agreements includes:

 

  • Trends in microbiome dealmaking in the biopharma industry since 2010
  • Analysis of microbiome deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life microbiome deals
  • Access to over 170 microbiome deals
  • The leading microbiome deals by value since 2010
  • Most active microbiome dealmakers since 2010
  • The leading microbiome partnering resources

 

 In Global Microbiome Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Global Microbiome Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of microbiome deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of microbiome agreements with numerous real life case studies
  • Comprehensive access to over 170 actual microbiome deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of  microbiome deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading microbiome deals by value since 2010
  • Identify the most active microbiome dealmakers since 2010
  • Detailed access to actual microbiome contracts enter into by the leading fifty bigpharma
  • Insight into the terms included in microbiome agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Microbiome dealmaking

 

2.1. Introduction
2.2. Microbiome partnering over the years
2.3. Most active Microbiome dealmakers
2.4. Microbiome partnering by deal type
2.5. Microbiome partnering by therapy area
2.6. Deal terms for Microbiome partnering
2.6.1 Microbiome partnering headline values
2.6.2 Microbiome deal upfront payments
2.6.3 Microbiome deal milestone payments
2.6.4 Microbiome royalty rates

 

Chapter 3 – Leading Microbiome deals

 

3.1. Introduction
3.2. Top Microbiome deals by value

 

Chapter 4 – Most active Microbiome dealmakers

 

4.1. Introduction
4.2. Most active Microbiome dealmakers
4.3. Most active Microbiome partnering company profiles

 

Chapter 5 – Microbiome contracts dealmaking directory

 

5.1. Introduction
5.2. Microbiome contracts dealmaking directory

 

Chapter 6 – Microbiome dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Microbiome deals by company A-Z

 

Appendix 2 – Microbiome deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Microbiome deals by deal type

 

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

 

Appendix 4 – Microbiome deals by therapy area

 

Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Microbiome partnering since 2010
Figure 2: Active Microbiome dealmaking activity since 2010
Figure 3: Microbiome partnering by deal type since 2010
Figure 4: Microbiome partnering by disease type since 2010
Figure 5: Microbiome deals with a headline value
Figure 6: Microbiome deals with an upfront value
Figure 7: Microbiome deals with a milestone value
Figure 8: Microbiome deals with a royalty rate value
Figure 9: Top Microbiome deals by value since 2010
Figure 10: Most active Microbiome dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Pharma, Abbvie, ADL Bionatur Solutions, AIDS Clinical Trials Group, Alimentary Health, Allergan, ALS Association, Amag Pharmaceuticals, American Type Culture Collection (ATCC), Argonne National Laboratory, Ariana Pharma, Arranta Bio, Assembly Biosciences, AstraZeneca, Azitra, BASF, Bayer, Baylor College of Medicine, Baylor Miraca Genetics Laboratories, Beam Therapeutics, Bertin Pharma, Bill and Melinda Gates Foundation, Bio-Rad Laboratories, BIOASTER, Biocodex Microbiota Foundation, Biocore, Biofortis, Biomecite Diagnostics, Biomica, Biomillenia, BiomX, BionX Medical Technologies, Bio Palette, Biosortia Pharmaceuticals, Bloom Science, Boehringer Ingelheim, Boston University School of Medicine, Brigham and Women's Hospital, Bristol-Myers Squibb, CARB-X, Carbiotix, Cedars-Sinai Medical Center, Centers for Disease Control and Prevention, Centre Leon Berard, Centre National de la Recherche Scientifique, Centro Sperimentale del Latte, Children's Hospital Boston, Circuit Clinical, Clalit Health Services, Commense, Companion PBx, Compass Minerals Plant Nutrition, ConsortiaTX, CoreBiome, Cornell University, CosmosID, Crohn's and Colitis Foundation of America, CryoXtract, Dana-Farber Cancer Institute, DayTwo, DDL Diagnostic Laboratory, Department of Health and Human Services, Dermala, Diversigen, DuPont Pharmaceuticals, DuPont Pioneer, Eagle Genomics, EcoMetrix, Emulate, EnBiotix, Enterome Bioscience, EpiBiome, Evelo Biosciences, Evogene, Evolve BioSystems, Evotec, ExeGi Pharma, Ferring Pharmaceuticals, Finch Therapeutics, Food Marble Digestive Health, Forsyth Institute, French National Institute for Agricultural Research, Galmed Pharmaceuticals, Genentech, General Automation Lab Technologies, Genetic Analysis, Genewiz, Genome and Company, GenomeQuest, Georges Francois Leclerc Center, German Cryo, Gilead Sciences, Ginkgo BioWorks, Glycosyn, Hackensack Meridian Health, Hamilton Company, Harvard School of Public Health, Harvard University, Helomics, HLH BioPharma Vertriebs, Holobiome, Hospital of University of Strasbourg, Human Longevity, Hy Laboratories, IBM, Innovate Biopharmaceuticals, Inserm, Inspirotec, Institut De Recherche Pour Le Developpement (IRD), Institute For Life Science Entrepreneurship (ILSE), Institut Gustave Roussy, Institut National Recherche Agronomique, Intract Pharma, Intralytix, Ipsen, ISOThrive, Jackson Laboratory, Janssen Biotech, Janssen Human Microbiome Institute, Janssen Research & Development, Janssen Therapeutics, J Craig Venter Institute, Jennewein Biotechnologie, Johns Hopkins University, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Kaleido Biosciences, Karolinska Institute, Keio Gijuku University, Kenneth Rainin Foundation (KRF), Kindstar Globalgene Technology, King's College Hospital, Kings College London, L'Oreal, Lawrence Livermore National Laboratory, Leiden University, Leidos, Les Laboratoires Servier, LNC, Locus Biosciences, MaaT Pharma, Macrogen, Marrone Bio Innovations, Massachusetts General Hospital, Mawi DNA Technologies, Mayo Clinic, MD Anderson Cancer Center, Medical College of Wisconsin, Medical University of Graz, Memorial Sloan Kettering Cancer Center, Merck KGaA, Metabiomics, MetaboGen, Metabolon, Metagenics, Metanome, Microbiotica, Microsoft, MilliporeSigma, Monsanto, MRM Health, MyBiotics Pharma, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Psoriasis Foundation, Nestle Health Science, Norgen Biotek, North Zealand University Hospital, NuBiyota, Nutricion, Nutrilinea, NYU Langone Medical Center, Oncodesign, One Codex, OpenBiome, OpGen, OptiBiotix, Origin Biosciences, OSEO, Owlstone Medical, Pathogenica, Pfizer, Pharmabiota, Pharmatest Services, Pierre Fabre, Precision Biomonitoring, Prescient Medical, Psomagen, PureTech Health, Qiagen, Quark Venture, Quimica Europea, Rebiotix, Ritter Pharmaceuticals, Roswell Park Cancer Institute, Ruggles Family Foundation, SACCO, Salix Pharmaceuticals, Sanofi, SATT Lutech, Second Genome, Seres Therapeutics, Seven Bridges Genomics, Sirenas, Stanford Cancer Institute, Stanford University School of Medicine, Symbiotix Biotherapies, Synergie Lyon Cancer, Synlogic, Synthetic Biologics, Taconic Biosciences, Takeda Pharmaceutical, Tata Chemicals, Texas Children’s Hospital, The BioCollective, The Parker Institute For Cancer Immunotherapy, Thermo Fisher Scientific, Toulouse University Hospital, Transgene, Tsinghua University, uBiome, UCB, Universite catholique de Louvain, University College Cork, University College Hospital, Ibadan, University of Adelaide, University of Alberta, University of British Columbia, University of Buffalo, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Irvine, University of Cape Town, University of Chicago, University of Cincinnati, University of Heidelberg, University of Maryland, University of Maryland Institute for Genome Sciences (IGS), University of Maryland School of Medicine, University of Maryland Ventures, University of Nebraska, University of Pennsylvania, University of Rhode Island, University of South Alabama (USA) Mitchell Cancer Institute, University of Texas, University of Verona, University of Washington, University Pierre Marie Curie, Valbiotis, Vedanta Biosciences, Venture Life, Vertex Pharmaceuticals, Viome, Washington University in St Louis, Weizmann Institute, Wellcome Trust, Western Connecticut Health Network, Xycrobe Therapeutics, Yeda Research and Development Company, Yili Industrial Group, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.